Evidence Table 167. KQ4—Continuous data—Area under the curve (AUC)

| **Author Year****Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Additional comments**  | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Kim 201035Cross-over | ng\*h/mL (0 - ∞); measured after single dose of ticlopidine and single dose Ginkgo biloba | Low and/or Moderate | Ticlopidine (250; single dose) | Ginkgo biloba (0.08; single dose) | 24 | Mean: 3466.00SD: 1548.80 | GMR: 3145.00 | GMRdiff: 1.10Lower: 1.00Upper: 1.20 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 24 | Mean: 3240.00SD: 1592.3 | GMR: 2568.00 |
| Tankanow 200365Cross-over | ng\*h/mL (0 - ∞); Measured after 10 days digoxin or 21 days digoxin + hawthorn | Low (healthy) | Digoxin (0.25) | Hawthorn (0.9) | 8 | Mean: 73.00SD: 20.00 | - | - | - | Medium |
| No treatment | 8 | Mean: 79.00SD: 26.00 | - |
| Mauro 200343Cross-over | ng\*h/mL (0 - ∞); Measured after single-dose administration of digoxin following 7 days pre-treatment with Ginkgo biloba or no pre-treatment | Low (healthy) | Digoxin (0.5; single dose) | *Ginkgo biloba* (0.24) | 8 | Mean: 25.6SD: 13.2 | - | - | - | Medium |
| No treatment | 8 | Mean: 21.00SD: 8.6 | - |

| Evidence Table 167. KQ4—Continuous data—Area under the curve (AUC) (continued) |
| --- |
| **Author Year****Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Additional comments**  | **Overall Risk of Bias (ROB) Assessment** |
| Jiang 200433Cross-over | R-Warfarin:µg/mL\*hr (0 - ∞); measured after single dose warfarin following 1 week pretreatment with ginseng or no pretreatment. Subjects followed for one more week post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Ginseng (3) | 12 | Mean: 108.1SD: 18.3Lower: 95.9Upper:120.2 | - | GMRdiff: 0.91Lower: 0.84Upper: 0.99 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 120.9SD: 32.9Lower: 99.0Upper: 142.7 | - |
| S-Warfarin:µg/mL\*hr (0 - ∞); measured after single-dose warfarin following 1 wk pretreatment with ginseng or no pretreatment. Subjects followed for 1 wk post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Ginseng (3) | 12 | Mean: 57.8SD: 7.4Lower: 53.1Upper: 62.5 | *-* | GMRdiff:0.89Lower: 0.82Upper: 0.98 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 65.4SD: 13.8Lower: 56.6Upper: 74.1 | *-* |
| Jiang 200532Cross-over | R-Warfarin:µg\*h/mL (0 - ∞); measured after single dose warfarin following 1 week pretreatment with Ginger, Ginkgo biloba or no pretreatment. Subjects followed for one more week post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Ginger (3.6) | 12 | - | - | GingerGMRdiff: 1.00Lower: 0.92Upper:1.07Ginkgo bilobaGMRdiff: 0.98Lower: 0.91Upper:1.06 | Upper and lower limits of between group difference = 90% CI | Medium |
| Ginkgo biloba(12)  | 12 | - | - |
| No treatment | 12 | - | - |
| S-Warfarin:µg\*h/mL (0 - ∞); measured after single-dose warfarin following 1 wk pretreatment with Ginger, Ginkgo biloba or no pretreatment. Subjects followed for 1 wk post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Ginger (3.6) | 12 | - | - | GingerGMRdiff: 0.95Lower: 0.89Upper:1.03Ginkgo bilobaGMRdiff: 0.97Lower: 0.89Upper:1.03 | Upper and lower limits of between group difference = 90% CI | Medium |
| *Ginkgo biloba* (12) | 12 | - | - |
| No treatment | 12 | - | - |
| Hajda 201028Cross over | ng\*h/mL (0-24 hours) | Low (healthy) | Simvastatin (20) | Garlic extract (600 mg twice daily) | 10 | Mean: 22.1SD: 25.7 | - | GMR (95% CI): 1.37 (0.88, 2.12) | - | Medium |
| No treatment | 10 | Mean: 11.2SD: 5.7 | - |
| Hajda 201028Cross over | ng\*h/mL (0-24 hours) | Low (healthy) | Pravastatin (20) | Garlic extract (600 mg twice daily) | 10 | Mean: 35.4SD: 15.5 | - | GMR (95% CI): 0.94 (0.65, 1.36) | - | Medium |
| No treatment  | 10 | Mean: 41.8SD: 24.1 | - | - |
| Gosai 200826Cross-over | ng\*h/ml; 2 weeks treatment; Day 14 steady state | Low (healthy) | Rovustatin (40) | Omega-3 fatty acids (EPA, DHA or both) (4) | 42 | Mean: 231.35SD: 93.15 | GMR = 213.73 | GMRdiff: 1.05Lower: 0.99Upper: 1.10 | % coefficient of variation:Omega-3: 40.26Control: 33.18Intra % coefficient of variation (Omega-3): 14.5Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 41 | Mean: 215.77SD: 71.60 | GMR = 204.19 |
| Yuan 200471 | Change from wk1 to w4 (µg/mL/d); steady state: assessed after 3 days warfarin treatment before and after 3 weeks 3 weeks treatment with ginseng or placebo | Low and/or Moderate | Warfarin (5) | Ginseng (2) | 12 | - | Medianchange­: -0.40RangeL: -1.20H: 0.20 | Median­diff: -0.64Range:L: -1.25H: -0.13 | - | Medium |
| Placebo | 8 | - | Medianchange­: 0.18RangeL: -0.35H: 1.40 |
| Di Spirito 200819Cross-over | Atorvastatin; Day 14 steady state (ng\*h/mL) over final dosing interval; 2 weeks treatment | Low (healthy) | Atorvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 49 | Mean: 212.50SD: 46.70 | - | GMRdiff: 1.03Lower: 0.97Upper: 1.09 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 49 | Mean: 207.20SD: 45.70 | - |
| 2-hydroxytorvastatin; Day 14 steady state; (ng\*h/mL); 2 weeks treatment | Low (healthy) | Atorvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 49 | Mean: 275.00SD: 37.90 | - | GMRdiff: 0.95Lower: 0.85Upper: 1.06 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 49 | Mean: 273.02SD: 35.90 | - |
| Mohammed Abdul 200849Cross-over | R-Warfarin:µg/mL\*h (0 - ∞); measured after single dose warfarin following 2 wks pretreatment with garlic or no pretreatment. Subjects followed for one more week post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Garlic (4; 7.42 mg allicin) | 12 | Mean: 105.00Lower: 96.30Upper: 113.70 | - | GMRdiff: 0.99Lower: 0.87Upper:1.13 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 108.70Lower: 90.00Upper: 127.30 | - |
| S-Warfarin:µg/mL\*h (0 - ∞); measured after single dose warfarin following 2 wks pretreatment with garlic or no pretreatment. Subjects followed for one more week post warfarin dose | Low (healthy) | Warfarin (25; single dose) | Garlic (4; 7.42 mg allicin) | 12 | Mean: 65.50Lower: 55.30Upper: 75.60 | - | GMRdiff: 1.06Lower: 0.95Upper:1.19 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 60.30Lower: 54.50Upper: 66.10 | - |
| McKenney 200645Cross-over | Simvastatin; AUCss over final dosing interval (ng\*h/mL); 2 wk treatment. | Low and/or Moderate | Simvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 21 | Mean: 125.10SD: 62.90 | - | - | - | Medium |
| No treatment | 18 | Mean: 116.60SD: 64.00 | - |
| Beta-hydroxy simvastatin: AUCss over final dosing interval (ng\*h/mL); 2 wk treatment. | Low and/or Moderate | Simvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 20 | Mean: 83.00SD: 42.20 | - | - | - | Medium |
| No treatment | 17 | Mean: 83.90SD: 44.40 | - |
| Abdul 20101Cross-over | R-Warfarin:mg\*h/mL (0 - ∞); measured after single dose warfarin following 2 wks pretreatment with Echinacea or no pretreatment. Subjects followed for one more week post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | *Echinacea* (5.1; 23 mg total alkamides) | 12 | Mean: 74.9Lower: 62.5Upper: 87.2 | - | GMRdiff: 0.95Lower: 0.88Upper: 1.03 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment  | 12 | Mean: 79.4Lower: 65.4Upper: 93.4 | - |
| S-Warfarin:mg\*h/mL (0 - ∞); measured after single dose warfarin following 2 wks pretreatment with Echinacea or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | *Echinacea* (5.1; 23 mg total alkamides) | 12 | Mean: 49.0Lower: 40.0Upper: 57.9 | - | GMRdiff: 0.92Lower: 0.85Upper: 1.99 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 53.9Lower: 42.9Upper: 64.8 |  |